ReviewBone marrow transplantation2016
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.Blood advances · 2024Trial
- Isatuximab-pomalidomide-dexamethasoneHaematologica · 2024Trial
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.Leukemia · 2020Trial
- Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.International journal of hematology · 2019Trial
- Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.British journal of haematology · 2017Trial
- Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma.NPJ systems biology and applications · 2025Article
- Relapsed/refractory multiple myeloma: standard of care management of patients in the Gulf region.Clinical hematology international · 2025Review
- Article
- Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.BMC cancer · 2024Article
- Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results.EJHaem · 2023Review
- Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications.Biomarker research · 2023Review
- Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- The Burden of a Multiple Myeloma Diagnosis on Patients and Caregivers in the First Year: Western European Findings.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Effects of comprehensive care in patients with multiple myeloma with cardiac dysfunction.American journal of translational research · 2021Article
- Safety and efficacy of chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma with renal impairment.Bone marrow transplantation · 2020Article
- c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.European journal of haematology · 2020Article
- Review
- Analyzing Survival Rate of Leukemia Patients Applying Long Term Exponential Model.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone.World journal of oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of modern therapies such as thalidomide, bortezomib and lenalidomide coupled with upfront high-dose therapy and autologous stem cell transplant (ASCT) has resulted in improved survival in patients with newly diagnosed multiple myeloma (MM). However, patients with relapsed/refractory multiple myeloma (RRMM) often have poorer clinical outcomes and might benefit from novel therapeutic strategies. Emerging therapies, such as deacetylase inhibitors, monoclonal antibodies and new proteasome inhibitors, appear promising and may change the therapeutic landscape in RRMM. A limited number of studies has shown a benefit with salvage ASCT in patients with RRMM, although there remains ongoing debate about its timing and effectiveness. Improvement in transplant outcomes has re-ignited a debate on the timing and possible role for salvage ASCT and allogeneic stem cell transplant in RRMM. As the treatment options for management of patients with RRMM become increasingly complex, physicians must consider both disease- and patient-related factors in choosing the appropriate therapeutic approach, with the goal of improving efficacy while minimizing toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.